Stability Guidelines WHO

87

© World Health Organization

WHO Technical Report Series, No. 953, 2009

Annex 2

Stability testing of active pharmaceutical ingredients

and fi nished pharmaceutical products

1. Introduction

1.1 Objectives of these guidelines

1.2 Scope of these guidelines

1.3 General principles

2. Guidelines

2.1 Active pharmaceutical ingredient …………………

2.1.1 General

2.1.2 Stress testing

2.1.3 Selection of batches

2.1.4 Container closure system

2.1.5 Specifi cation

2.1.6 Testing frequency

2.1.7 Storage conditions……

2.1.8 Stability commitment

2.1.9 Evaluation

2.1.10 Statements and labelling

2.1.11 Ongoing stability studies

2.2 Finished pharmaceutical product

2.2.1 General

2.2.2 Selection of batches

2.2.3 Container closure system

2.2.4 Specifi cation

2.2.5 Testing frequency

2.2.6 Storage conditions

2.2.7 Stability commitment

2.2.8 Evaluation

2.2.9 Statements and labelling

2.2.10 In-use stability

2.2.11 Variations

2.2.12 Ongoing stability studies

3. Glossary

References

Appendix 1

Long-term stability testing conditions as identifi ed by WHO Member States.

Appendix 2

Examples of testing parameters…

Appendix 3

Recommended labelling statements…

88

1. Introduction

1.1 Objectives of these guidelines

These guidelines seek to exemplify the core stability data package

required for registration of active pharmaceutical ingredients (APIs) and

fi nished pharmaceutical products (FPPs), replacing the previous WHO

guidelines in this area (1,2). However, alternative approaches can be used

when they are scientifi cally justifi ed. Further guidance can be found in

International Conference on Harmonisation (ICH) guidelines (3) and in

the WHO guidelines on the active pharmaceutical ingredient master fi le

procedure (4).

It is recommended that these guidelines should also be applied to products

that are already being marketed, with allowance for an appropriate transition

period, e.g. upon re-registration or upon re-evaluation.

1.2 Scope of these guidelines

These guidelines apply to new and existing APIs and address information

to be submitted in original and subsequent applications for marketing

authorization of their related FPP for human use. These guidelines are not

applicable to stability testing for biologicals (for details on vaccines please

see WHO guidelines for stability evaluation of vaccines (5)).

1.3 General principles

The purpose of stability testing is to provide evidence of how the quality

of an API or FPP varies with time under the infl uence of a variety of

environmental factors such as temperature, humidity and light. The

stability programme also includes the study of product-related factors

that infl uence its quality, for example, interaction of API with excipients,

container closure systems and packaging materials. In fi xed-dose

combination FPPs (FDCs) the interaction between two or more APIs also

has to be considered.

As a result of stability testing a re-test period for the API (in exceptional

cases, e.g. for unstable APIs, a shelf-life is given) or a shelf-life for the FPP

can be established and storage conditions can be recommended.

Various analyses have been done to identify suitable testing conditions

for WHO Member States based on climatic data and are published in

the literature (6–9) on the basis of which each Member State can make

its decision on long-term (real-time) stability testing conditions. Those

Member States that have notifi ed WHO of the long-term stability testing

conditions they require when requesting a marketing authorization are

listed in Appendix 1.

89

2. Guidelines

2.1 Active pharmaceutical ingredient

2.1.1 General

Information on the stability of the API is an integral part of the systematic

approach to stability

...